Literature DB >> 34250413

Molecular Tumor Board Guides Successful Treatment of a Rare, Locally Aggressive, Uterine Mesenchymal Neoplasm.

Elaine M Walsh1,2, Deyin Xing3, Melissa H Lippitt4,5, Amanda N Fader4, Stephanie L Wethington4, Christian F Meyer1, Stephanie L Gaillard1,4.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34250413      PMCID： PMC8232830          DOI： 10.1200/PO.20.00189

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN： 2473-4284


× No keyword cloud information.
  35 in total

1.  Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

Authors:  James E Butrynski; David R D'Adamo; Jason L Hornick; Paola Dal Cin; Cristina R Antonescu; Suresh C Jhanwar; Marc Ladanyi; Marzia Capelletti; Scott J Rodig; Nikhil Ramaiya; Eunice L Kwak; Jeffrey W Clark; Keith D Wilner; James G Christensen; Pasi A Jänne; Robert G Maki; George D Demetri; Geoffrey I Shapiro
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

2.  LRRFIP1, a new FGFR1 partner gene associated with 8p11 myeloproliferative syndrome.

Authors:  G Soler; S Nusbaum; B Varet; E A Macintyre; M Vekemans; S P Romana; I Radford-Weiss
Journal:  Leukemia       Date:  2009-04-16       Impact factor: 11.528

3.  Drastic initial response and subsequent response to two ALK inhibitors in a patient with a highly aggressive ALK-rearranged inflammatory myofibroblastic tumor arising in the pleural cavity.

Authors:  Akira Ono; Haruyasu Murakami; Masakuni Serizawa; Kazushige Wakuda; Hirotsugu Kenmotsu; Tateaki Naito; Tetsuhiko Taira; Yasuhiro Koh; Yasuhisa Ohde; Takashi Nakajima; Masahiro Endo; Toshiaki Takahashi
Journal:  Lung Cancer       Date:  2016-07-05       Impact factor: 5.705

4.  ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor.

Authors:  C M Coffin; A Patel; S Perkins; K S Elenitoba-Johnson; E Perlman; C A Griffin
Journal:  Mod Pathol       Date:  2001-06       Impact factor: 7.842

5.  Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.

Authors:  Patrick Schöffski; Jozef Sufliarsky; Hans Gelderblom; Jean-Yves Blay; Sandra J Strauss; Silvia Stacchiotti; Piotr Rutkowski; Lars H Lindner; Michael G Leahy; Antoine Italiano; Nicolas Isambert; Maria Debiec-Rychter; Raf Sciot; Thomas Van Cann; Sandrine Marréaud; Axelle Nzokirantevye; Sandra Collette; Agnieszka Wozniak
Journal:  Lancet Respir Med       Date:  2018-04-15       Impact factor: 30.700

6.  Inflammatory myofibroblastic tumor of the uterus: clinical and pathologic review of 10 cases including a subset with aggressive clinical course.

Authors:  Carlos Parra-Herran; Charles M Quick; Brooke E Howitt; Paola Dal Cin; Bradley J Quade; Marisa R Nucci
Journal:  Am J Surg Pathol       Date:  2015-02       Impact factor: 6.394

7.  Dramatic response to alectinib in inflammatory myofibroblastic tumor with anaplastic lymphoma kinase fusion gene.

Authors:  Masafumi Saiki; Fumiyoshi Ohyanagi; Ryo Ariyasu; Junji Koyama; Tomoaki Sonoda; Shingo Nishikawa; Satoru Kitazono; Noriko Yanagitani; Atsushi Horiike; Hironori Ninomiya; Yuichi Ishikawa; Makoto Nishio
Journal:  Jpn J Clin Oncol       Date:  2017-12-01       Impact factor: 3.019

Review 8.  Epithelioid inflammatory myofibroblastic sarcoma treated with ALK inhibitor: a case report and review of literature.

Authors:  Qiuyu Liu; Yunzhen Kan; Yuewu Zhao; Hui He; Lingfei Kong
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

9.  STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion.

Authors:  Vivek Subbiah; Caitlin McMahon; Shreyaskumar Patel; Ralph Zinner; Elvio G Silva; Julia A Elvin; Ishwaria M Subbiah; Chimela Ohaji; Dhakshina Moorthy Ganeshan; Deepa Anand; Charles F Levenback; Jenny Berry; Tim Brennan; Juliann Chmielecki; Zachary R Chalmers; John Mayfield; Vincent A Miller; Philip J Stephens; Jeffrey S Ross; Siraj M Ali
Journal:  J Hematol Oncol       Date:  2015-06-11       Impact factor: 17.388

10.  An Unusual Case of Systemic Inflammatory Myofibroblastic Tumor with Successful Treatment with ALK-Inhibitor.

Authors:  Sanjivini V Jacob; John D Reith; Angerika Y Kojima; William D Williams; Chen Liu; Lizette Vila Duckworth
Journal:  Case Rep Pathol       Date:  2014-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.